Professional and Linguistic Assessments Board (PLAB) Practice Exam

The long-term management strategy for patients who have experienced a transient ischemic attack (TIA) typically includes the use of antiplatelet agents to reduce the risk of subsequent strokes. Clopidogrel is an effective antiplatelet medication that is often recommended for patients with a TIA, especially those who may have contraindications to aspirin or for those who have had a recurrent event while on aspirin therapy. Clopidogrel helps to inhibit platelet aggregation, thereby decreasing the likelihood of clot formation that can lead to a stroke. It is particularly useful in patients with a higher risk profile for stroke, and its use is supported by various clinical guidelines. The decision to prescribe clopidogrel can depend on factors like the patient’s overall health, the specific characteristics of the TIA, and their risk factors for future cerebrovascular events. While aspirin and statins can be part of the management strategy, the choice of clopidogrel is particularly relevant due to its efficacy in specific scenarios, especially in preventing further ischemic incidents in patients who have already had a transient event. Warfarin is generally not indicated for TIA unless there is an additional indication, such as atrial fibrillation or significant embolic risk factors.